Dai­ichi Sankyo looks to bring FLT3 drug back from the dead with late-stage win in ear­ly AML pa­tients

Dai­ichi Sankyo was on the re­ceiv­ing end of an FDA slap­down more than two years ago for FLT3 drug quizar­tinib and some flim­sy da­ta in acute myeloid leukemia. Look­ing to sal­vage a bad sit­u­a­tion, Dai­ichi is now tout­ing re­sults in ear­li­er AML pa­tients with hopes for a bet­ter out­come with reg­u­la­tors.

Quizar­tinib added to a chemo reg­i­men and then con­tin­ued so­lo sig­nif­i­cant­ly ex­tend­ed the lives of pa­tients with new­ly di­ag­nosed acute myeloid leukemia with the FLT3-ITD mu­ta­tion over chemo alone, ac­cord­ing to topline re­sults from the Phase III QuAN­TUM-FIRST study re­leased Fri­day.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN